Physician profile
Nicholas E Simpson
NPI 1174174775
$11,568.20
in general payments reported to CMS, 2019-2025
46 companies · $2,752 in 2025
The $2,752 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.30 · 2022: $2,080 · 2023: $3,213 · 2024: $3,478 · 2025: $2,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,306 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,305.61 |
| Education | $136.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,068.19 | 2022-2025 | Bimzelx, Cimzia, Briviact |
| Abbvie INC. | $1,773.85 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,202.24 | 2022-2025 | |
| Janssen Biotech, INC. | $1,083.81 | 2022-2025 | Tremfya, Remicade, Simponi Aria |
| Amgen INC. | $1,004.97 | 2022-2025 | Enbrel, Tavneos, Otezla |
| Lilly USA, LLC | $928.06 | 2021-2024 | Taltz, Zepbound |
| Pfizer INC. | $869.31 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $496.35 | 2022-2025 | Saphnelo, Farxiga |
| Genzyme Corporation | $283.20 | 2023-2025 | |
| Viiv Healthcare Company | $156.21 | 2025 | Cabenuva, Apretude, Dovato |
| Teva Pharmaceuticals USA, INC. | $156.15 | 2022-2023 | |
| Sandoz INC. | $136.39 | 2023-2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.01 | 2023-2024 | Cyltezo, Ofev |
| Biohaven Pharmaceutical Holding Company Ltd. | $108.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $106.53 | 2022-2025 | Orencia |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.